To assess the relevance of these specific T cell responses against the six identified epitopes in melanoma patients, we performed ELISPOT assays on CD8+ tumor-infiltrating lymphocyte (TIL) populations from 22 HLA-A *0201 melanoma patients from a previous clinical trial.32,33. The gene discussed is CD8A; the disease is melanoma.